Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

British Journal of Clinical Pharmacology

Volumn 78, Issue 6, 2014, Pages 1407-1418

  Riggs, Matthew M ^a   Seman, Leo J ^b   Staab, Alexander ^c   MacGregor, Thomas R ^b   Gillespie, William ^a   Gastonguay, Marc R ^a   Woerle, Hans J ^c   Macha, Sreeraj ^b  

^a Metrum Research Group LLC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BI 10773; Empagliflozin; Exposure response analyses; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DIABETIC PATIENT; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; EVALUATION STUDY; FEMALE; GENITAL CANDIDIASIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; INCIDENCE; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION; VULVOVAGINITIS; ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84911476493     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12453     Document Type: Article

References (28)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71.
3. Chao EC. A paradigm shift in diabetes therapy-dapagliflozin and other SGLT2 inhibitors. Discov Med 2011; 11: 255-63.
4. Moe OW, Wright SH, Palacín M. Renal handling of organic solutes. In: Brenner and Rector's The Kidney, ed. Brenner BM. Philadelphia: Saunders Elsevier, 2008; 214-47.
5. Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, Eickelmann P, Mark M. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 2012; 14: 94-6.
6. Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with T2DM. Diabetes Ther 2013; 4: 331-45.
7. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-21.
8. Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ. Pharmacokinetics, pharmacodynamics, safety and tolerability of four weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013; 4: 613-7.
9. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 721-8.
10. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-60.
11. Beal SL, Sheiner LB, Boeckmann AJE. NONMEM Users Guide: Part I-VII (1989-2006). Ellicott City, MD, USA: Icon Development Solutions, 2006.
12. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. New York, USA: Chapman & Hall/CRC, 2004.
13. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92.
14. Hastie T, Tibshirani R. Generalized Additive Models. Boca Raton, FL, USA: Chapman & Hall/CRC, 1999.
15. Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. Cambridge, UK: Cambridge University Press, 2003.
16. Bachman WJ, Gillespie WR. Truncated sigmoid Emax models: a reparameterization of the sigmoids Emax model for use with truncated PK/PD data. Clin Pharmacol Ther 1998; 63: 199.
17. Schoemaker RC, van Gerven JM, Cohen AF. Estimating potency for the Emax-model without attaining maximal effects. J Pharmacokinet Biopharm 1998; 26: 581-93.
18. Cockcroft ADW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-9.
20. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-10.
21. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
22. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006; 21: 2166-71.
23. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-42.
24. Samtani MN. Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm Drug Dispos 2010; 31: 162-77.
25. Yao Z, Krzyzanski W, Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn 2006; 33: 167-93.
26. Devineni D, Marbury TC, Curtin CR, Vaccaro N, Wexler D, Vandebosch A, Wajs E, Polidori D. Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non-diabetic subjects. J Am Soc Nephrol 2012; 23: 961A.
27. Kasichayanula S, Liu X, Benito MP, Yao M, Pfister M, Lacreta FP, Humphreys WG, Boulton DW. The influence of kidney function on dapagliflozin exposure, metabolism and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013; 76: 432-44.
28. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014; 16: 215-22.